Patients with Unresectable Stage III Non-Small Cell Lung Cancer Eligible to Receive Durvalumab in Clinical Practice

被引：0
|
作者：
Furuhashi, K. [1 ]
Hataji, O. [1 ]
Nakamura, Y. [1 ]
Suzuki, Y. [1 ]
Sakaguchi, T. [1 ]
Ito, K. [1 ]
Fujiwara, K. [1 ]
Nishii, Y. [1 ]
Taguchi, O. [1 ]
机构：
[1] Matsusaka Municipal Hosp, Resp Ctr, Matsusaka City, Mie, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
chemoradiotherapy; durvalumab; Non-Small Cell Lung Cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP1.18-19
引用
收藏
页码：S1104 / S1104
页数：1
相关论文
共 50 条
  • [1] Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria
    Sakaguchi, Tadashi
    Ito, Kentaro
    Furuhashi, Kazuki
    Nakamura, Yuki
    Suzuki, Yuta
    Nishii, Yoichi
    Taguchi, Osamu
    Hataji, Osamu
    RESPIRATORY INVESTIGATION, 2019, 57 (05) : 466 - 471
  • [2] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
  • [3] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [4] The toxicity profile of durvalumab leading to interruption for stage III non-small cell lung cancer in clinical practice
    Teshirogi, T.
    Izumi, H.
    Sakai, T.
    Udagawa, H.
    Sugiyama, E.
    Zenke, Y.
    Umemura, S.
    Matsumoto, S.
    Yoh, K.
    Goto, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1378 - S1378
  • [5] Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer
    Shaverdian, Narek
    Offin, Michael D.
    Rimner, Andreas
    Shepherd, Annemarie F.
    Wu, Abraham J.
    Rudin, Charles M.
    Hellmann, Matthew D.
    Chaft, Jamie E.
    Gomez, Daniel R.
    RADIOTHERAPY AND ONCOLOGY, 2020, 144 : 101 - 104
  • [6] Original Research Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
    Riudavets, Mariona
    Auclin, Edouard
    Mosteiro, Miguel
    Dempsey, Naomi
    Majem, Margarita
    Lobefaro, Riccardo
    Lopez-Castro, Rafael
    Bosch-Barrera, Joaquim
    Pilotto, Sara
    Escalera, Elena
    Tagliamento, Marco
    Mosquera, Joaquin
    Zalcman, Gerard
    Aboubakar-Nana, Frank
    Ponce, Santiago
    Dal Maso, Alessandro
    Spotti, Martina
    Mielgo-Rubio, Xabier
    Mussat, Elodie
    Reyes, Roxana
    Benitez, Jose-Carlos
    Lupinacci, Lorena
    Duchemann, Boris
    De Giglio, Andrea
    Blaquier, Juan
    Audigier-Valette, Clarisse
    Scheffler, Matthias
    Nadal, Ernest
    Lopes, Gilberto
    Signorelli, Diego
    Garcia-Campelo, Rosario
    Menis, Jessica
    Bluthgen, Virginia
    Campayo, Marc
    Recondo, Gonzalo
    Besse, Benjamin
    Planchard, David
    Mezquita, Laura
    EUROPEAN JOURNAL OF CANCER, 2022, 167 : 142 - 148
  • [7] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [8] Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer
    Tomasini, Pascale
    Greillier, Laurent
    Boyer, Arnaud
    Jeanson, Arnaud
    Barlesi, Fabrice
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1032 - S1036
  • [9] Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study
    Teng, Feifei
    Ge, Hong
    Wang, Buhai
    Xu, Yaping
    Meng, Xue
    Wang, Suzhen
    Xing, Ligang
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Real world assessment of clinical benefit with consolidation durvalumab following chemoradiotherapy in stage III unresectable non-small cell lung cancer
    Marur, Shanthi
    Mangurian, Mark
    Wise, Corey
    Pozotrigo, Melissa
    Marur, Shika
    Norden, Andrew D.
    Toler, Andrew
    Bobolts, Laura Rose
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345